Chemotherapy-induced uridine diphosphate release promotes breast cancer metastasis through P2Y6 activation
Metrics: HTML 1518 views | ?
Xiaobin Ma1, Xinhua Pan1, Yinglei Wei1, Binhe Tan1, Linli Yang1, Hua Ren1, Min Qian1, Bing Du1
1Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China
Bing Du, email: firstname.lastname@example.org
Keywords: UDP, P2Y6, MMP-9, metastasis, breast cancer
Received: November 30, 2015 Accepted: March 28, 2016 Published: April 09, 2016
Although purinergic signaling is important in regulation of immune responses, the therapeutic potential of it in the tumor microenvironment is little defined. In this study, we demonstrate that UDP/P2Y6 signaling facilitates breast cancer metastasis both in vitro and in vivo. We found that P2Y6 is not only aberrantly expressed and mutated in most tumor types, but also highly correlated with poor prognosis in breast cancer patients. Furthermore, the migration and invasion of breast cancer cells was obviously increased by UDP and blocked by P2Y6 specific inhibitor MRS2578 and P2Y6 shRNA. Similar results was also found in breast cancer cell metastasis mouse model. Interestingly, the endogenous agonist UDP was released significantly by doxorubicin treated cells. In addition, the expression and enzyme activity of MMP-9 were both promoted by UDP and inhibited by MRS2578 or P2Y6 shRNA. Furthermore, UDP-induced cell invasion was blocked by an MMP-9 inhibitor. Mechanistically, the MAPKs and NF-κB signaling pathways, known to be involved in regulation of MMP-9 expression, were both activated by UDP. Taken together, our study reveals a relationship between extracellular danger signals and breast cancer metastasis, which suggests the potential therapeutic significance of UDP/P2Y6 signaling in cancer therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.